Gilead Sciences Announces Acquisition of CymaBay Therapeutics for $4.3 Billion

Details

entered into a definitive agreement to acquire CymaBay Therapeutics, Inc. for $32.50 per share in cash, totaling approximately $4.3 billion. The acquisition, which is expected to close in the first quarter of 2024, will bolster Gilead's liver portfolio with the addition of seladelpar, CymaBay's investigational treatment for Primary Biliary Cholangitis (PBC). The transaction is subject to customary closing conditions, including regulatory approvals and a minimum tender of CymaBay shares.

Items reported

Exhibits (2)

About Gilead Sciences Inc.

Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.